RxDoctor Payments Data

Samer Kawak, MD

Colon & Rectal Surgery · Noblesville, INNPI 1174901573

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (52.4%), education and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 82.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $2,175 and has fallen 92.7% since, to $160 in 2025.

$3,954in general payments, 2019–2025

Across 41 payments — averaging $96.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Medtronic$149
  • Braintree Laboratories, Inc.$124
  • Boston Scientific$113
  • TELA Bio, Inc.$100
  • Axonics, Inc.$64
  • plus $130 from 4 others

What the payments were for

  • Travel & lodging$2,07352%
  • Food & beverage$80120%
  • Education$1,00025%
  • Gifts$802%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,954 in reported general payments places this provider in the 60th percentile of 54 colon & rectal surgery providers in Indiana.

See all colon & rectal surgery providers in Indiana

Medicare billing

Part B allowed, 2024
$67,585
Medicare patients
150
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf71$11,646
LoperamideLoperamide Hcl15$288
Neomycin Sulfate29$155
Ondansetron Hcl89$113
Metronidazole29$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$124$11,64671 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 54 colon & rectal surgery providers in Indiana.

Other colon & rectal surgery in Noblesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →